

Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)

Meeting – December 13, 2017 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. November 8, 2017 DUR Minutes – Vote
- B. November 8, 2017 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/SoonerPsych Program Update – See Appendix B

- A. Medication Coverage Activity for November 2017
- B. Pharmacy Help Desk Activity for November 2017
- C. SoonerPsych Program Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Mavyret™ (Glecaprevir/Pibrentasvir) and Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) – See Appendix C

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nichols, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Baxdela™ (Delafloxacin Injection and Tablets), Ofloxacin 300mg Tablets, Minolira™ (Minocycline Extended-Release Tablets), Solosec™ (Secnidazole Oral Granules), and Vabomere™ (Meropenem/Vaborbactam Injection) – See Appendix D

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Duzallo® (Lesinurad/Allopurinol) – See Appendix E

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

8. Action Item – Annual Review of Phosphate Binders – See Appendix F

- A. Current Prior Authorization Criteria
- B. Utilization of Phosphate Binders
- C. Prior Authorization of Phosphate Binders
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Phosphate Binders

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

9. Action Item – Annual Review of Soliris® (Eculizumab) – See Appendix G

- A. Current Prior Authorization Criteria
- B. Utilization of Soliris® (Eculizumab)
- C. Prior Authorization of Soliris® (Eculizumab)
- D. Market News and Updates
- E. Soliris® (Eculizumab) for Myasthenia Gravis (MG) Summary
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

10. Annual Review of Duchenne Muscular Dystrophy (DMD) Medications and 30-Day Notice to Prior Authorize Emflaza® (Deflazacort) – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of DMD Medications [Exondys 51™ (Eteplirsen)]
- C. Prior Authorization of DMD Medications [Exondys 51™ (Eteplirsen)]
- D. Market News and Updates
- E. Emflaza® (Deflazacort) Product Summary
- F. Guideline Recommendations
- G. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

11. Annual Review of Maintenance Asthma and Chronic Obstructive Pulmonary Disease (COPD) Medications and 30-Day Notice to Prior Authorize ArmonAir™ RespiClick® (Fluticasone Propionate), Trelegy™ Ellipta® (Fluticasone Furoate/Umeclidinium/Vilanterol), Qvar® RediHaler™ (Beclomethasone Dipropionate), AirDuo™ RespiClick® (Fluticasone Propionate/Salmeterol), and Fasenra™ (Benralizumab) – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of Maintenance Asthma and COPD Medications
- C. Prior Authorization of Maintenance Asthma and COPD Medications
- D. Market News and Updates
- E. ArmonAir™ RespiClick® (Fluticasone Propionate Inhalation Powder) Product Summary
- F. Trelegy™ Ellipta® (Fluticasone Furoate/Umeclidinium/Vilanterol Inhalation Powder) Product Summary
- G. Qvar® RediHaler™ (Beclomethasone Dipropionate HFA) Product Summary
- H. AirDuo™ RespiClick® (Fluticasone Propionate/Salmeterol Inhalation Powder) Product Summary
- I. Fasenra™ (Benralizumab Injection) Product Summary
- J. College of Pharmacy Recommendations
- K. Utilization Details of Maintenance Asthma and COPD Medications
- L. Utilization Details of Asthma Monoclonal Antibodies (Pharmacy Claims)
- M. Utilization Details of Asthma Monoclonal Antibodies (Medical Claims)
- N. Utilization Details of Inhaled Corticosteroids

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

12. Annual Review of Anti-Emetic Medications and 30-Day Notice to Prior Authorize Varubi® IV (Rolapitant) and Cinvanti™ (Aprepitant) – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Emetic Medications
- C. Prior Authorization of Anti-Emetic Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Anti-Emetic Medications

Items to be presented by Dr. Nichols, Dr. Muchmore, Chairman:

13. 30-Day Notice to Prior Authorize Zilretta™ (Triamcinolone Acetonide Extended-Release Injectable Suspension) – See Appendix K

- A. Introduction
- B. Zilretta™ (Triamcinolone Acetonide Extended-Release Injectable Suspension) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

14. Annual Review of Ophthalmic Allergy Medications and 30-Day Notice to Prior Authorize Zerviate™ (Cetirizine Ophthalmic Solution) – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Ophthalmic Allergy Medications
- C. Prior Authorization of Ophthalmic Allergy Medications
- D. Market News and Updates
- E. Zerviate™ (Cetirizine Ophthalmic Solution) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Ophthalmic Allergy Medications

Non-Presentation; Questions Only:

15. Industry News and Updates – See Appendix M

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

16. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix N

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

17. Future Business* (Upcoming Product and Class Reviews)

No live meeting scheduled for January. January will be a packet only meeting.

- A. Injectable and Vaginal Progesterone Products
- B. Potassium Binding Medications
- C. Defitelio® (Defibrotide)
- D. Kanuma® (Sebelipase Alfa)
- E. Zinplava™ (Bezlotoxumab)
- F. Lumizyme® (Alglucosidase Alfa)

**Future business subject to change.*

18. Adjournment